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Abstract
Background: Several lines of evidence suggest a possible functional role of Matrix metalloproteinase -2 (MMP-2) in
obesity. The aim of this study was to evaluate the role of MMP-2 promoter polymorphisms in percentage body fat
(PBF) as a measure of childhood obesity in a New Zealand population.
Findings: 546 samples from the Auckland Birthweight Collaborative (ABC) study were genotyped for the three
MMP-2 promoter SNPs -1306 C/T (rs243865), -1575G/A (rs243866) and -790 T/G (rs243864) using the Sequenom
genotyping platform. The results demonstrated that an MMP-2 promoter haplotype is associated with PBF in New
Zealand 7 year old children.
Conclusion: We have previously determined that environmental factors are associated with differences in PBF in
this study group, and now we have demonstrated a possible genetic contribution.
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Introduction
Obesity is reaching epidemic proportions worldwide and is
now occurring at younger ages. In New Zealand, one in
twelve youngsters aged 2 to 14 years are considered to be
obese and one in five are classified as overweight (A Por-
trait of Health, 2006/07 New Zealand Health Survey).
Obese children are at increased risk of a number of
health problems including diabetes, sleep problems, joint
problems, early puberty or menarche, asthma and other
respiratory problems [1]. Obesity often persists into
adulthood and is associated with increased morbidity and
mortality [2,3].
Body mass index (BMI) is the most common method
used to determine obesity. However, although BMI may
facilitate an adult obesity diagnosis, using this method to
diagnose obesity in children may yield more ambiguous
results, as BMI is a marker of relative weight and doesn’t
directly measure body fat [4]. Measuring percentage body
fat (PBF) may be a more effective method of diagnosing
obesity in children.
Childhood obesity is thought to be the result of an inter-
play between many genetic and environmental factors. We
have previously investigated environmental factors in the
Auckland Birthweight Collaborative (ABC) study, and
found maternal overweight/obesity, maternal age, female
gender, sedentary activity time and hours of television
viewing to be independently associated with PBF in 7 year
old children [5]. We are now interested in identifying pos-
sible genetic factors.
Several lines of evidence suggest a possible functional
role of Matrix metalloproteinase -2 (MMP-2) in obesity.
The main role of MMP-2 is in the degradation of type IV
collagen, the major structural component of basement
membranes. However, the enzyme also has activity toward
a spectrum of functional molecules including growth fac-
tor-binding proteins and growth factor receptors, which
are known to be involved in obesity. For example, MMP-2
can cleave insulin-like growth factor-binding proteins and
release insulin-like growth factors [6]. It has also been sug-
gested that MMP-2 plays an important role in adipose tis-
sue development [7-10]. Furthermore, tissue degradation
by MMP-2 is pivotal to inflammation [11], and obesity is
associated with low grade inflammation.
We undertook an association analysis of 3 functional
polymorphisms in the promoter of the MMP-2 gene
(-1306C/T, -1575G/A and -790T/G), to investigate the
possible role for MMP-2 as a genetic risk factor for obe-
sity (in terms of increased PBF) in the ABC study.
* Correspondence: ang.morgan@auckland.ac.nz
1Discipline of Nutrition, FMHS, The University of Auckland, New Zealand
Full list of author information is available at the end of the article
Morgan et al. BMC Research Notes 2011, 4:253
http://www.biomedcentral.com/1756-0500/4/253
© 2011 Morgan et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
The -1306 C/T (rs243865) polymorphism is located in
the CCACC box of the Sp1-binding site and displays a
strikingly lower promoter activity with the T allele [12].
The -1575G/A (rs243866) variant is located immediately
5’ to a half-palindromic potential oestrogen receptor
binding site and the G allele functions as an enhancer
[13]. The -790 T/G (rs243864) SNP is located in the
inverted GATA-1 element (CTATCT) in the promoter
region. Three important transcription factors (GKLF-gut
enriched Krueppel-like factor, S8, and Evil-ectopic viral
integration site 1 encoded factor) may bind with the T
allele but not with the G allele [14].
Methods
Participants
The ABC study was designed as a case-control study to
determine risk factors for small for gestational age
(SGA) infants and has been described in detail pre-
viously [15]. Data have been collected at birth, 1, 3.5, 7
and most recently 11 years of age. The original sample
at birth resulted in a sample of 1714 subjects, of which
871 mothers were identified in the obstetric data to be
of European ethnicity. At the age of 1 and 3.5 follow up
of non-European ethnicities was poor resulting in a lack
of ability to generalise the results from these children to
their particular populations. As a result follow-up from
the age of 7 has only been carried out on those children
whose mothers were identified as European ethnicity at
birth.
Percentage body fat (PBF) at age 7 years was the out-
come measure analysed in this paper. This was mea-
sured using bioelectrical impedance analysis (BIA). This
allows calculation of fat free mass which was calculated
according to the formula of Schaeffer et al [16] and con-
sequently percentage body fat.
At 11 years 546 participants consented to collection of
peripheral blood (n = 397) or a buccal swab (n = 149)
for DNA extraction and genotyping.
Genotyping
DNA was extracted from the blood/buccal samples
using Qiagen’s DNA extraction kit and following the
manufacturer’s instructions. Genotyping was performed
with the MassARRAY and iPlex systems of the Seque-
nom genotyping platform (Sequenom, San Diego, CA),
which uses the MALDI-TOF primer extension assay
[17,18], according to manufacturers’ recommendations.
The SNPs were in a multiplex with SNPs from a differ-
ent study that used the same samples. Assays were opti-
mized in 24 samples consisting of 20 reference Centre
d’Etude du Polymorphisme Humain (CEPH) samples
and 4 blanks. All sample plates contained cases, con-
trols, blanks, CEPH and duplicate samples. Quality con-
trol measures included independent double genotyping,
blind to sample identity and blind to the other caller,
and comparison of our CEPH genotypes to those in the
HapMap http://www.hapmap.org.
Statistical analysis
SNPs were tested for deviation from Hardy-Weinberg
equilibrium (HWE) using a chi-square goodness-of-fit
test.
A Generalised linear model (GLM) was used to test
the linearity of genotype-phenotype relationship for
quantitative traits. For linearity of the genotype-pheno-
type relationship for quantitative traits, each SNP was
coded 0, 1, and 2 for each tested allele [19,20]. For
example, G/G, G/T, and T/T were coded as 0, 1, and 2
for the T allele for rs243864. All analyses were con-
trolled for SGA status due to the disproportionate sam-
ple of SGA and AGA at birth (phase 1). Multivariable
analyses also controlled for environmental factors pre-
viously shown to be independently related in this dataset
to PBF namely sex of the child, maternal body mass
index, maternal age at the birth of the child, hours of
television watched per day, and the amount of time
spent in sedentary activities [5].
To determine LD (linkage disequilibrium) between the
SNPs we uploaded our data into haploview [21]. Haplo-
type blocks were defined using the default algorithm
which uses confidence intervals [22]. Haplotype analysis
was carried out using HAPLO.SCORE in R to test for
association of the haplotypes with PBF.
Statistical analyses were carried out using R [23] and
SAS (V9.1 SAS Institute., Cary, NC, USA). A p-value
less than 0.05 was considered statistically significant.
Ethical approval
The study received ethical approval from the Northern
Regional Ethics Committee. Signed consent for the
study and extraction of DNA was given by the parents
of the children and assent also given by the child.
Results
The genotype counts (frequencies) for the three geno-
typed SNPs are shown in table 1. Each of the SNPs met
Hardy Weinberg criteria. All 3 SNPs were found to be
associated with PBF (table 2). The T allele of rs243864,
the C allele of rs243865 and the G allele of rs243866
were associated with a higher PBF as compared to the
alleles G, T and A respectively. However, the results just
Table 1 Genotype counts (frequencies) for the MMP2
promoter SNPs in the ABC samples
rs243866: AA = 31 (0.060) AG = 191 (0.350) GG = 305 (0.590)
rs243865: TT = 34 (0.066) CT = 179 (0.347) CC = 303 (0.587)
rs243864: GG = 33 (0.063) GT = 185 (0.350) TT = 310 (0.587)
Morgan et al. BMC Research Notes 2011, 4:253
http://www.biomedcentral.com/1756-0500/4/253
Page 2 of 5
fell below statistical significance after adjustment for
environmental factors previously shown to be indepen-
dently related in this dataset to PBF: sex of the child,
maternal body mass index, maternal age at the birth of
the child, hours of television watched per day, and the
amount of time spent in sedentary activities [5] (table
3). The SNPs were not associated with any of the con-
founding factors (data not shown, but available on
request).
The 3 MMP-2 promoter SNPs are in high LD with
each other (Figure 1), so we undertook haplotype analy-
sis. The GTA (rs243864, rs243865, and 243866 respec-
tively) haplotype was significantly associated with PBF
(p = 0.019). Individuals with the GTA haplotype had
lower PBF in comparison to individuals with the TCG
haplotype (table 4). After adjustment for confounding
factors, the GTA haplotype remained significantly asso-
ciated with PBF (p = 0.040) (table 5).
Discussion
This paper reports for the first time the role of MMP-2
promoter polymorphisms in childhood obesity as mea-
sured using PBF. Although we were unable to demon-
strate an association for the 3 SNPs individually after
correcting for confounding factors, the GTA (rs243864,
rs243865, 243866) haplotype was statistically significant.
It has previously been suggested that studying haplo-
types could be more informative than the study of indi-
vidual SNPs [24,25].
Genetic variation in MMP-2 has been previously
investigated for association with obesity, in adults from
Korea [26]. Whereas we have focussed on promoter
SNPs and PBF, Han et al. investigated coding SNPs and
looked for association with BMI. They found 2 SNPs
(out of the 5 investigated) to be associated with over-
weight/obesity, and also identified a haplotype as signifi-
cant. Taken together with our own results, it can be
concluded that MMP-2 may be an important suscept-
ibility gene for obesity in both children and adults.
The genetic association we report in the MMP-2 pro-
moter may result from altered MMP expression, as the
3 SNPs investigated are all functional SNPs capable of
affecting transcriptional activity. Indeed, associations
with MMP-2 circulating levels in mouse models and
obese children and adults have been previously reported.
High expression of MMP-2 has been demonstrated in
adipose tissue of mice with nutritionally induced obesity,
as well as in genetically obese mice [9,10,27]. Bouloumiè
et al. [8] provided the first evidence that human adipose
Table 2 Effect of MMP2 promoter SNPs on PBF
SNP Tested allele Estimate (95% CI) p
rs243864 T 1.32 (0.08 - 2.56) 0.037
rs243865 C 1.40 (0.16 - 2.64) 0.027
rs243866 G 1.42 (0.16 - 2.69) 0.028
Table 3 Effect of MMP2 promoter SNPs on PBF after
adjustment for confounding factors
SNP Tested allele Estimate (95% CI) p
rs243864 T 0.990 (-0.19 - 2.17) 0.099
rs243865 C 1.144 (-0.03 - 2.31) 0.055
rs243866 G 1.164 (-0.03 - 2.36) 0.057
Figure 1 LD plot for MMP-2 promoter SNPs. LD (D’) plot of
MMP2 genotyped SNPs. LD between rs243866 and rs243865: D’ = 1,
r2 = 1. LD between rs243865 and rs243864: D’ = 1, r2 = 0.989. LD
between rs243866 and rs243864: D’ = 0.994, r2 = 0.983.
Table 4 Haplotype analysis
rs243864 rs243865 rs243866 hap.
freq
coef se p
haplo.base T C G 0.766 23.63 0.71
mmp2hap.1 G T A 0.231 -1.56 0.66 0.019
mmp2hap.
rare
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tissue releases MMP-2. Later two studies by the same
group described decreased circulating levels of MMP-2
(and increased levels of MMP-9 and TIMP-1) in obese
children [28,29]. Whilst a study examining obesity in
adults demonstrated increased MMP-2 (and MMP-9)
levels [30].
Additional studies are now required to further investi-
gate MMP-2 involvement in the development of obesity.
It may be also be worth considering other matrix
metalloproteinases.
In conclusion the results presented here demonstrate
that an MMP-2 promoter haplotype is associated with
PBF in New Zealand 7 year old children. We have pre-
viously determined that environmental factors are asso-
ciated with differences in PBF in the ABC study, and now
we have demonstrated a possible genetic contribution.
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